Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer

Fig. 3

Endpoint Analysis of ID8 Tumors Treated with Therapeutic MnNPs. A Treatment schematic for development of ID8 ovarian tumor model and 3-day MnNP treatment. Serum levels of (B) AST, (C) ALT, and (D) BUN were evaluated at endpoint. AST and ALT were significantly elevated in IκBα-MnNP treatment, but still within normal ranges while BUN levels were unchanged (n = 5, *p < 0.05). Changes in (E) ascites volume and (F) tumor weight at takedown (n = 10, color indicates experimental groupings). RNA isolated from the ascites cells revealed increases in the inflammatory cytokines (G) CCL3 and (H) TNF-α (PBS control n = 5, Scr-MnNP n = 3, IκBα-MnNP n = 4, *p < 0.05). I Cells in the ascites also significantly decreased in expression of IL-6 in both MnNP treatments (PBS control and IκBα-MnNP n = 4, Scr-MnNP n = 5, *p < 0.05)

Back to article page